- Home
- OB vs IMMP Comparison
OB vs IMMP Comparison
Compare OB & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- IMMP
- Stock Information
- Founded
- OB 2006
- IMMP 1987
- Country
- OB United States
- IMMP Australia
- Employees
- OB N/A
- IMMP N/A
- Industry
- OB Industrial Machinery/Components
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- OB Industrials
- IMMP Health Care
- Exchange
- OB Nasdaq
- IMMP Nasdaq
- Market Cap
- OB 269.6M
- IMMP 304.0M
- IPO Year
- OB 2021
- IMMP N/A
- Fundamental
- Price
- OB $6.61
- IMMP $1.91
- Analyst Decision
- OB Buy
- IMMP Buy
- Analyst Count
- OB 5
- IMMP 2
- Target Price
- OB $6.66
- IMMP $8.50
- AVG Volume (30 Days)
- OB 288.1K
- IMMP 95.6K
- Earning Date
- OB 02-27-2025
- IMMP 02-27-2025
- Dividend Yield
- OB N/A
- IMMP N/A
- EPS Growth
- OB N/A
- IMMP N/A
- EPS
- OB N/A
- IMMP N/A
- Revenue
- OB $903,518,000.00
- IMMP $2,563,302.00
- Revenue This Year
- OB $0.80
- IMMP N/A
- Revenue Next Year
- OB $8.13
- IMMP $47.79
- P/E Ratio
- OB N/A
- IMMP N/A
- Revenue Growth
- OB N/A
- IMMP 9.59
- 52 Week Low
- OB $3.42
- IMMP $1.66
- 52 Week High
- OB $7.87
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- OB 50.89
- IMMP 40.99
- Support Level
- OB $6.36
- IMMP $2.00
- Resistance Level
- OB $6.53
- IMMP $2.05
- Average True Range (ATR)
- OB 0.27
- IMMP 0.09
- MACD
- OB -0.11
- IMMP -0.02
- Stochastic Oscillator
- OB 48.98
- IMMP 2.78
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.